Kevin Byrne
( out of 116 reviews )

Kevin Byrne, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

1950 Circle of Hope
Salt Lake City , UT 84112
Get Directions

Kevin Byrne, MD, Assistant Professor (Clinical), earned his medical degree at Boston University School of Medicine. He completed Adult Psychiatry residency at the University of Utah Spencer Fox Eccles School of Medicine where he served as Chief Resident. He is board certified in Psychiatry by the ABPN. Dr. Byrne's clinical interests include psychiatric care for people with cancer, existential distress, psychedelic treatments for mental health, treatment-resistant mood disorders, trauma and its related conditions, and advanced psychopharmacology. His research focuses on examining psychedelic treatments such as ketamine, MDMA, and psilocybin for the treatment of existential distress and other mental health conditions. Dr. Byrne is excited to be continuing his work as a member of the outpatient teams at the University of Utah Huntsman Mental Health Institute and at the Huntsman Cancer Hospital.

Specialties

Board Certification

American Board of Psychiatry & Neurology (Psychiatry)

Patient Rating

4.9 /5
( out of 116 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.

Aug 15, 2026
HUNTSMAN CANCER CENTER

Amazing Dr

Feb 05, 2026
HUNTSMAN CANCER CENTER

Dr. Byrne is absolutely fantastic with my treatment.

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

Kevin Byrne, MD, Assistant Professor (Clinical), earned his medical degree at Boston University School of Medicine. He completed Adult Psychiatry residency at the University of Utah Spencer Fox Eccles School of Medicine where he served as Chief Resident. He is board certified in Psychiatry by the ABPN. Dr. Byrne's clinical interests include psychiatric care for people with cancer, existential distress, psychedelic treatments for mental health, treatment-resistant mood disorders, trauma and its related conditions, and advanced psychopharmacology. His research focuses on examining psychedelic treatments such as ketamine, MDMA, and psilocybin for the treatment of existential distress and other mental health conditions. Dr. Byrne is excited to be continuing his work as a member of the outpatient teams at the University of Utah Huntsman Mental Health Institute and at the Huntsman Cancer Hospital.

Board Certification and Academic Information

Academic Departments Psychiatry -Assistant Professor (Clinical)
Academic Divisions Adult Psychiatry
Board Certification
American Board of Psychiatry & Neurology (Psychiatry)

Education history

Residency Adult Psychiatry - University of Utah Spencer Fox Eccles School of Medicine Chief Resident
Residency Adult Psychiatry - University of Utah Spencer Fox Eccles School of Medicine Resident
Professional Medical Medicine - Boston University School of Medicine M.D.
Undergraduate Computer Science - Pomona College B.A.

Selected Publications

Journal Article

  1. Lewis BR, Reid MJ, Novick AM, Byrne K, Niciu MJ, Fonzo GA, Meyer TD, Feifel D, El-Mallakh RS, Soares J, Suppes T, Barrett FS (2026). Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds. J Psychopharmacol, Epub ahead of print.
  2. Lewis BR, Hendrick J, Byrne K, Odette M, Wu C, Garland EL (2025). Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLoS Med, 22(9), e1004519.
  3. Lewis BR, Garland EL, Byrne K, Durns T, Hendrick J, Beck A, Thielking P (2023). HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer. J Pain Symptom Manage, 66(3), 258-269.
  4. Lewis BR, Byrne K, Hendrick J, Garland EL, Thielking P, Beck A (2023). Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial. J Psychedelic Stud.
  5. Byrne KJ, Lindsay S, Baker N, Schmutz C, Lewis B (2023). In naturalistic psychedelic use, group use is common and acceptable. J Psychedelic Stud.
  6. Turner DC, Edmiston AM, Zohner YE, Byrne KJ, Seigfreid WP, Girkin CA, Morris JS, Downs JC (2019). Transient Intraocular Pressure Fluctuations: Source, Magnitude, Frequency, and Associated Mechanical Energy. Invest Ophthalmol Vis Sci, 60(7), 2572-2582.
  7. Keefe KR, Byrne KJ, Levi JR (2018). Treating pediatric post-tonsillectomy pain and nausea with complementary and alternative medicine. Laryngoscope, 128(11), 2625-2634.
  8. Fowler ML, Zhu C, Byrne K, Lieber SB, Moore A, Shmerling RH, Paz Z (2017). Pathogen or contaminant? Distinguishing true infection from synovial fluid culture contamination in patients with suspected septic arthritis. Infection, 45(6), 825-830.

Review

  1. Lewis BR, Byrne K (2023). A Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder. [Review]. Focus (Am Psychiatr Publ), 21(3), 247-256.
  2. Lewis BR, Byrne K (2021). Is MDD the right target for early-stage psychedelic-assisted therapy trials? [Review]. J Psychedelic Stud, 5(2), 65-68.

Commentary

  1. Lewis BR, Byrne KJ, Beck A (2023). Group Format Psilocybin-Assisted Therapy: Commentary on the HOPE trial (HOPE: a pilot study of psilocybin-enhanced group psychotherapy in patients with cancer) . Journal of Anesthesiology and Pain Therapy, 4(3), 1-3.

News & Podcasts

News

Schedule Online